Skip to main content

Table 2 Ongoing treatments

From: COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area

 

COVID-19 patients, N pts/N evaluable (%)

RNA-positive subgroup, N pts/N evaluable (%)

Early breast cancer patients

N = 22

N = 22

 Surgery*

3/22 (14%)

3/22 (14%)

 Chemotherapy

8/22 (36%)

8/22 (36%)

  Epirubicin and cyclophosphamide

5/22 (23%)

5/22 (23%)

  Paclitaxel/docetaxel

2/22 (9%)

2/22 (9%)

 Radiation therapy

2/22 (9%)

2/22 (9%)

 Endocrine therapy

4/22 (18%)

4/22 (18%)

  Anti-estrogens

3/22 (14%)

3/22 (14%)

  Aromatase inhibitors

1/22 (4%)

1/22 (4%)

 Targeted therapy

3/22 (14%)

3/22 (14%)

  Trastuzumab

2/22 (9%)

2/22 (9%)

  Pertuzumab

1/22 (4%)

1/22 (4%)

  Trastuzumab emtansine

1/22 (4%)

1/22 (4%)

 None

6/22 (27%)

6/22 (27%)

  Pending surgery

5/22 (23%)

5/22 (23%)

  Pending radiation therapy

1/22 (4%)

1/22 (4%)

 Combination of any treatment

3/22 (14%)

3/22 (14%)

Metastastic breast cancer patients

N = 37

N = 19

 Surgery*

0 (0%)

0 (0%)

 Chemotherapy

21/37 (57%)

10/19 (53%)

  Capecitabine

7/37 (19%)

4/19 (21%)

  Paclitaxel/docetaxel

6/37 (16%)

3/19 (16%)

  Epirubicin and cyclophosphamide

1/37 (3%)

0 (0%)

  Vinorelbine

2/37 (5%)

0 (0%)

  Eribulin

1/37 (3%)

1/19 (5%)

  Gemcitabine

2/37 (5%)

1/19 (5%)

  Carboplatin

3/37 (8%)

1/19 (5%)

  Intrathecal chemotherapy

2/37 (5%)

2/19 (10%)

 Radiation therapy

2/37 (5%)

2/19 (10%)

 Endocrine therapy

15/37 (40%)

7/19 (37%)

  Anti-estrogens

3/37 (8%)

1/19 (5%)

  Aromatase inhibitors

11/37 (30%)

6/19 (32%)

  Selective estrogen receptor degrader

1/37 (3%)

0 (0%)

 Targeted therapy

16/37 (43%)

7/19 (37%)

  CDK4/6 inhibitor

9/37 (24%)

5/19 (26%)

  Trastuzumab

5/37 (13%)

2/19 (10%)

  Pertuzumab

4/37 (11%)

2/19 (10%)

  Everolimus**

2/37 (5%)

0 (0%)

 Immunotherapy

0 (0%)

0 (0%)

 Combination of any treatment

21/37 (57%)

8/19 (42%)

 None

1/37 (3%)

1/19 (5%)

Total

N = 59

N = 41

  1. Listed treatments were those ongoing within 30 days before COVID-19 diagnosis
  2. *Ongoing surgery includes 30 days from surgery
  3. **As recommended, patients stopped everolimus at the beginning of the pandemic